Which antibiotics should be used to empirically treat an adult patient for Staphylococcus species (including MRSA) and Pseudomonas aeruginosa?

Antibiotic Coverage for Staph and Pseudomonas

For empiric coverage of both Staphylococcus (including MRSA) and Pseudomonas aeruginosa, use an antipseudomonal beta-lactam (piperacillin-tazobactam 4.5g IV q6h, cefepime 2g IV q8h, or meropenem 1g IV q8h) PLUS vancomycin (15 mg/kg IV q8-12h targeting 15-20 mg/mL trough) or linezolid (600 mg IV q12h). 1

Clinical Decision Framework

The choice of antibiotics depends on your clinical context and risk stratification:

For High-Risk Patients or Recent Antibiotic Exposure

When treating patients at high risk of mortality (requiring ventilatory support, septic shock) or those who received IV antibiotics within the prior 90 days, dual antipseudomonal coverage is recommended 1:

Regimen structure:

• One antipseudomonal beta-lactam (choose one):
  • Piperacillin-tazobactam 4.5g IV q6h
  • Cefepime or ceftazidime 2g IV q8h
  • Imipenem 500mg IV q6h
  • Meropenem 1g IV q8h

PLUS a second agent from a different class (avoid two beta-lactams):

• Fluoroquinolone: Levofloxacin 750mg IV daily OR ciprofloxacin 400mg IV q8h
• Aminoglycoside: Amikacin 15-20 mg/kg IV daily, gentamicin 5-7 mg/kg IV daily, or tobramycin 5-7 mg/kg IV daily
• Aztreonam 2g IV q8h

PLUS MRSA coverage:

• Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL; consider loading dose 25-30 mg/kg for severe illness)
• OR Linezolid 600mg IV q12h 1

For Moderate-Risk Patients Without Recent Antibiotic Use

If MRSA risk factors are present (prior IV antibiotics within 90 days, unit with >20% MRSA prevalence, or unknown local prevalence) but not at high mortality risk, single antipseudomonal agent plus MRSA coverage is appropriate 1:

• One antipseudomonal beta-lactam (as listed above)
• PLUS vancomycin or linezolid (doses as above)

For Lower-Risk Patients

If no MRSA risk factors and not high mortality risk, a single antipseudomonal agent covering MSSA is sufficient:

• Piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem alone 1

Key Clinical Considerations

Local antibiogram is critical: The 2016 IDSA/ATS guidelines strongly emphasize that empiric regimens must be based on local pathogen distribution and susceptibility patterns 1. Your hospital's antibiogram should guide specific agent selection.

Avoid dual beta-lactams: When using two antipseudomonal agents, never combine two beta-lactams. The exception is aztreonam, which can be combined with another beta-lactam as it has different bacterial cell wall targets 1.

Structural lung disease: Patients with bronchiectasis or cystic fibrosis warrant dual antipseudomonal coverage regardless of other risk factors due to increased gram-negative infection risk 1.

Vancomycin vs. linezolid for MRSA: Both are strongly recommended as first-line agents for MRSA coverage 1. Linezolid may have advantages in pneumonia specifically, with some evidence suggesting superior clinical success rates compared to vancomycin (RR 1.71; 95%-CI 1.45-2.02) 2, though it carries higher adverse reaction rates 2.

Common Pitfalls

Overtreatment is harmful: Research shows that unnecessarily broad empiric antibiotics (including anti-MRSA and anti-Pseudomonal coverage when these organisms aren't present) are associated with increased mortality (OR 1.22; 95% CI 1.06-1.40) 3. De-escalate once cultures return.

Undertreatment is also harmful: Inadequate empiric coverage is associated with increased mortality (OR 1.19; 95% CI 1.03-1.37) 3. The prevalence of MRSA in culture-positive sepsis is approximately 11.7% and resistant gram-negatives 13.2% 3, making empiric broad coverage reasonable in appropriate clinical contexts.

Penicillin allergy: If severe penicillin allergy precludes beta-lactam use and aztreonam is chosen, ensure MSSA coverage is included separately 1.